Each 5 ml of reconstituted dry syrup contains Cefixime 50 mg and Clavulanic Acid 31.25 mg.

Ritecef CV-50 Dry Syrup combines Cefixime, a third-generation cephalosporin antibiotic, with Clavulanic Acid, a potent β-lactamase inhibitor, to provide enhanced antibacterial coverage against β-lactamase-producing organisms. This paediatric formulation is effective in the treatment of upper respiratory tract infections, otitis media, pharyngitis, tonsillitis, and acute exacerbations of chronic bronchitis caused by susceptible bacteria. The convenient dry syrup formulation ensures accurate dosing and improved compliance in children.

Ritecef CV-50 Dry Syrup is indicated for the treatment of upper respiratory tract infections (URTIs), otitis media, pharyngitis, tonsillitis, and acute exacerbations of chronic bronchitis caused by susceptible bacterial pathogens.

Cefixime is a semi-synthetic, oral third-generation cephalosporin with broad-spectrum bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. It acts by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. Clavulanic Acid is an irreversible β-lactamase inhibitor that protects Cefixime from enzymatic degradation by β-lactamase-producing bacteria, thereby extending its antibacterial spectrum and enhancing therapeutic efficacy.

For paediatric patients aged 6 months and older, the recommended dosage is 8 mg/kg/day, administered either as a single daily dose or in two divided doses of 4 mg/kg every 12 hours, or as directed by the treating physician.

Ritecef CV-50 Dry Syrup is contraindicated in patients with known hypersensitivity to Cefixime, other cephalosporins, Clavulanic Acid, or any component of the formulation.